Anti-Epidermal Growth Factor-like Protein 7 Antibody

Mouse Monoclonal Antibody specific to Epidermal Growth Factor-like Protein 7

Product Specifications

CAS Number

9007-83-4

Product Name Alternative

EGF-like protein 7, Multiple epidermal growth factor-like domains protein 7, Multiple EGF-like domains protein 7, NOTCH4-like protein, Vascular endothelial statin, VE-statin, Zneu1

Gene Name

EGFL7

NCBI Gene ID

UniProt

Q9UHF1

Cellular Locus

Secreted, extracellular space

Host

Mouse

Reactivity

Human

Immunogen

His-tagged EGFL-7 recombinant protein. Accession no. Q9UHF1.

Target Antigen

Epidermal growth factor-like protein 7

Target

Epidermal Growth Factor-like Protein 7

Clonality

Monoclonal

Isotype

IgG1

Type

Antibody

Applications

WB, IHC, ELISA

Field of Research

Growth Factors, Cytokines, Receptors

Purification Method

Purified by Protein A affinity chromatography

Dilution

Reconstitute lyophilized antibody using ultrapure to a final concentration no less than 100 ug/mL. Reconstitution with PBS or Tris buffer is acceptable if required. Protein carrier, biocide or cryopreservative can be added as needed. Aliquot and store at -20C for longterm storage. Dilute immediately prior to use.

Format

Purified

Form

Lyophilized

Buffer

Tris Buffer

Function

Regulates vascular tubulogenesis in vivo. Inhibits platelet-derived growth factor (PDGF)-BB-induced smooth muscle cell migration and promotes endothelial cell adhesion to the extracellular matrix and angiogenesis. {PubMed:23386126, PubMed:23639441}.

Additionnal Information

ELISA: use at 1-10ug/ml Immunoblotting: User should use at 1-5ug/ml. A band of ~30kDa is detected. Immunohistochemistry: Use at 2- 10ug/ml. These are recommended concentrations. End user should determine optimal concentrations for their applications.

Storage Conditions

This product is stable for at least one (1) year at -20°C to -70°C. Reconstituted product should be stored in appropriate aliquots to avoid repeated freeze-thaw cycles.

Specificity

This antibody reacts with human EGFL- 7 protein.

Formulation

Lyophilized, 0.1M Tris, 0.1M glycine, 2% sucrose, 1mg/ml.

Target Background

EGF-L7 (Epidermal Growth Factor Like Protein 7) is a multi-domain protein containing two EGF like domains and one EMI domain. It is expressed almost exclusively in endothelial cells and functions to promote normal development of the vascular system. EGF-L7 is capable of antagonistic binding to Notch receptors resulting in the inhibition of Notch signaling in HUVEC and neural stem cells. In research models inducing hypoxia and subsequent reoxygenation, (H/R), EGF- L7 can inhibit ICAM-1 expression and enhance the inhibition of NF-kappaB activation. Additionally, EGF-L7 is a chemoattractant for endothelial cells and binds to the extracellular matrix. The overexpression of EGF-L7 is observed in various cancers, and is generally correlated with increased metastasis and a poor prognosis.